Atrasentan is an endothelin A receptor antagonist used to reduce proteinuria in patients with primary IgA nephropathy. A medication used to reduce kidney damage in patients with a progressive kidney disease called IgA nephropathy.
- Mechanism
- Curator reviewed · 4 references
The pathogenesis of IgA nephropathy begins with abnormal O-glycosylation of IgA, leading to increased levels of galactose-deficient IgA. The immune system then produces autoantibodies against these altered IgA molecules, forming circulating immune complexes. These complexes deposit in the kidney's mesangium, triggering mesangial cell activation, complement system involvement, and the release of inflammatory cytokines, leading to inflammation, protein deposition, and fibrosis within the kidneys.
Amongst other downstream effects, the inflammation caused by immune complex deposition causes an upregulation in endothelin-1 (ET-1), which binds to endothelin A receptors (ETAR) on renal cells. The activation of ETAR has been implicated in podocyte damage, proteinuria, fibrosis, and further progression of kidney disease.
Atrasentan is a selective antagonist of ETAR, preventing the binding of ET-1 and thereby reducing the associated detrimental downstream effects.
- Primary indication
- Atrasentan is indicated to reduce proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk of rapid disease progression, generally a urine protein-to-creatinine ratio (UPCR) ≥1.5 g/g.Curator reviewed · 1 structured indication
- Formula / weight
- C29H38N2O6 · 510.6218 g/mol (avg)
- First approval
- Canada, 2026 · United States, 2025
- Code names
- ABT-627 · CHK-01
- Brand names
Resolves to
MOTJMGVDPWRKOC-QPVYNBJUSA-NSMILESCCCCN(CCCC)C(=O)CN1C[C@@H]([C@H]([C@@H]1C1=CC=C(OC)C=C1)C(O)=O)C1=CC2=C(OCO2)C=C1What you can answer from here — as of September 11, 2026
Which drugs share a target with Atrasentan, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account